Core Viewpoint - The company, Shunhao Co., announced an abnormal stock price fluctuation with a cumulative decline of over 20% from January 13 to January 15, 2026, indicating potential market concerns [1] Group 1: Stock Performance - The company's stock price experienced a significant drop, with a cumulative deviation exceeding 20% over three consecutive days [1] - The company confirmed that there were no corrections or supplementary information regarding previous disclosures, and its operations remain normal [1] Group 2: Business Developments - The company plans to sell a 60% stake in Shanghai Luxin Electronics, which may impact its net profit [1] - In June 2025, the company invested 110 million yuan in Trajectory Light, holding a 19.30% stake, and plans to increase its investment by 74.98 million yuan in January 2026, raising its stake to 28.68% [1] Group 3: Financial Performance - For the first three quarters of 2025, the company's net profit was 67.319 million yuan, reflecting a year-on-year increase of 20.29% [1] - The company's non-recurring net profit for the same period was 22.1344 million yuan, showing a significant year-on-year decline of 61.12% [1]

此次交易有利于公司聚焦核心主业，预计将增加公司2026年度所有者权益约516万元。 人民财讯1月14日电，康隆达（603665）1月14日公告，公司及全资子公司金昊新材料共同持有的全资子 公司泰安欣昌、胡艳霞与NIANGADOU DISTRIBUT COMPAGNIE SAU(简称"NIANGADOU")签订《股 份出售协议》，拟将持有的Suay Chin International Pte.Ltd.(简称"Suay Chin")100%股权出售给 NIANGADOU，交易价格704.67万英镑(折合人民币约6636万元)。其中泰安欣昌持有Suay Chin51%股 权，胡艳霞持有Suay Chin49%股权。 ...

每经AI快讯，康隆达1月14日晚间发布公告称，为聚焦核心主业，优化公司资产结构及资源配置，提高 公司资产运营效率和降低管理成本，公司及全资子公司金昊新材料共同持有的全资子公司泰安欣昌、胡 艳霞与NIANGADOU 签订了《股份出售协议》，拟将持有的Suay Chin International Pte. Ltd100%股权出 售给NIANGADOU，交易价格为7046670英镑（折合人民币约6636万元）。其中泰安欣昌持有Suay Chin51%股权，对应金额约为3384.36万元；胡艳霞持有Suay Chin49%股权，对应金额约为3251.64万 元。本次交易完成后，公司将不再持有Suay Chin股权，Suay Chin不再纳入公司合并报表范围。 （记者 曾健辉） 每经头条（nbdtoutiao）——海利生物增值9倍并购的企业，估值8个月"腰斩"，其第一大客户竟是尚未 成立的公司，离奇的事还不少…… ...

Group 1 - The core viewpoint of the article is that 蓝帆医疗 (Blue Sail Medical) plans to sell its wholly-owned subsidiary 武汉必凯尔救助用品有限公司 (Wuhan Bikaier) to focus on its core business and enhance cash reserves [1] - The transaction aims to activate existing assets and shorten management radius, indicating a strategic shift towards operational efficiency [1] - The buyer of the subsidiary is 武汉明德生物科技股份有限公司 (Wuhan Mingde Biotechnology), a company listed on the Shenzhen Stock Exchange, which is not considered a related party, thus the transaction is not classified as a major asset restructuring [1]

Core Viewpoint - Kosen Technology announced that it received a regulatory letter from the Shanghai Stock Exchange regarding the sale of its wholly-owned subsidiary Kosen Medical's equity, highlighting concerns over the company's ongoing losses while the subsidiary reported revenue and profit [1] Financial Performance - Kosen Medical achieved revenues of 366 million yuan and 354 million yuan for the first three quarters of 2024 and 2025, respectively [1] - The net profits for Kosen Medical were reported at 41.12 million yuan and 47.24 million yuan for the same periods [1] - In contrast, the parent company continues to incur losses during this timeframe [1] Regulatory Requirements - The exchange has requested the company to provide additional disclosures, including the reasons for the losses and the financial impact of the transaction [1] - An independent board member's interviews and document reviews found no evidence of related party transactions or undisclosed interests in the deal [1] Internal Transactions - A special audit covering the period from 2018 to September 30, 2025, confirmed that transactions between Kosen Medical and the parent company, as well as its subsidiaries, were necessary, reasonably priced, and had commercial substance [1]

Core Viewpoint - The company plans to sell its wholly-owned subsidiary, Changsha Yushun Display Technology Co., Ltd., to Huanuo Xingkong Technology Co., Ltd. for a total consideration of approximately 112 million yuan, aiming to optimize its asset structure and enhance operational efficiency [1] Group 1 - The board of directors and the supervisory board of the company will hold meetings on June 16, 2025, to review the proposal for the sale of the subsidiary [1] - The transaction involves Huanuo Xingkong acquiring 100% of Changsha Yushun's equity through a cash payment, with a total payment of 140 million yuan to be made to the company and its subsidiary, Xinhui Kai Technology (Shenzhen) Co., Ltd. [1] - The company has already received the total payment of 140 million yuan from Huanuo Xingkong and Changsha Yushun as of the announcement date [1] Group 2 - Following the completion of the equity transfer, Changsha Yushun will no longer be included in the company's consolidated financial statements [1] - The transaction is part of the company's strategy to promote high-quality development and improve asset operation efficiency [1]

Transaction Overview - Zhejiang Dahua Technology Co., Ltd. has approved the sale of 32.7321% equity in its subsidiary Hangzhou Huacheng Network Technology Co., Ltd. for a price of 71.68329 million RMB, corresponding to an investment of 25.5 million RMB [1] - The buyer is Shanghai Zhicheng Enterprise Management Partnership (Limited Partnership), which has been changed to Shanghai Zhicheng Technology Co., Ltd. [1] Transaction Progress - The change of the buyer does not involve any adjustments to other transaction terms [1] - Shanghai Zhicheng Technology Co., Ltd. has a registered capital of 115.7 million RMB and is engaged in various technology and consulting services [1] - The financial data of the controlling shareholder shows total assets of approximately 809.1 million RMB and a net asset of approximately 80.9 million RMB [1] Company Impact - The company no longer holds equity in Huacheng Network, and it will not be included in the company's consolidated financial statements [1]

Core Viewpoint - The independent directors of Zhongyifeng Lopuskin Material Technology Co., Ltd. have approved the sale of equity in a controlling subsidiary, which aligns with the company's overall business strategy to focus on core operations and optimize business layout [1][2]. Group 1 - The meeting was convened and conducted in accordance with relevant laws and regulations, with all independent directors participating and voting by signature [1]. - The voting results showed unanimous support for the proposal, with 3 votes in favor and no votes against or abstentions [1]. - The independent directors believe that the pricing of the related transaction is fair and based on assessment results negotiated between the parties, ensuring no harm to the company or its shareholders, particularly minority shareholders [2]. Group 2 - The proposal regarding the sale of subsidiary equity and related transactions will be submitted for review at the 22nd meeting of the sixth board of directors [2].